Immune checkpoint inhibitor ‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

ConclusionsORR and PFS were significantly better in ILD patients than in irAEs ‐non‐ILD and non‐irAEs patients. Pre‐existing history of IP was an independent risk factor for ILD‐induced ICIs.

Source: Thoracic Cancer - February 28, 2020 Category: Cancer & Oncology Authors: Teppei Sugano, Masahiro Seike, Yoshinobu Saito, Takeru Kashiwada, Yasuhiro Terasaki, Natsuki Takano, Kakeru Hisakane, Satoshi Takahashi, Toru Tanaka, Susumu Takeuchi, Akihiko Miyanaga, Yuji Minegishi, Rintaro Noro, Kaoru Kubota, Akihiko Gemm Tags: ORIGINAL ARTICLE Source Type: research